EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Intraoperative and Perioperative Outcomes of Breast-Conserving Surgery After Neoadjuvant Systemic Therapy: A Retrospective Cohort Study

Yashasvini Sampathkumar, Rebecca Yu, Tiana Y Sepahpour, Hanae K Tokita, William E Rosa, Anoushka Afonso, Andrew Vickers, Melissa Assel, Anita Mamtani, Jennifer R Majumdar

Clinical Breast Cancer · 2026

DOI: 10.1016/j.clbc.2026.08.005 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Clinical Breast Cancer, 2026. Verfasst von Yashasvini Sampathkumar und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY. Hauptthemen laut MEDLINE: Breast Neoplasms, Neoadjuvant Therapy, Mastectomy, Segmental, Postoperative Complications. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Memorial Sloan-Kettering Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Neoadjuvant chemotherapy (NAC), with or without immunotherapy (IO), is increasingly used in patients with breast cancer and may facilitate breast-conserving surgery (BCS). Because these therapies may alter physiologic reserve and perioperative care needs, we evaluated their associations with anesthetic management and postoperative recovery. PATIENTS AND METHODS: This retrospective cohort study included 374 patients with stage II-III breast cancer undergoing BCS at a high-volume ambulatory cancer center. Patients were categorized as receiving NAC, NAC + IO, or no neoadjuvant therapy. Primary outcomes were use of general anesthesia (GA) and postanesthesia care unit length of stay (PACU LOS). Multivariable models adjusted for age, body mass index, receptor subtype, tumor stage, and nodal status; the PACU LOS model additionally adjusted for surgery start time. Secondary outcomes included intraoperative propofol and opioid dosing per surgical hour and 30-day postoperative adverse events. RESULTS: NAC was associated with a 29% higher adjusted probability of GA use (95% confidence interval [CI], 15%-43%) and a 1.4-h longer PACU LOS (P = .001). Among patients receiving NAC, IO was associated with an 18% lower adjusted probability of GA use (95% CI, 3.1%-33%) and a 0.96-h shorter PACU LOS (P = .031). Intraoperative opioid requirements and 30-day postoperative adverse events did not differ meaningfully across treatment groups. Differences in propofol dosing were statistically significant but modest. CONCLUSION: Neoadjuvant treatment exposure was associated with differences in anesthetic approach and postoperative recovery despite low complication rates. These findings support treatment-informed perioperative planning and multidisciplinary coordination for patients undergoing BCS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsNeoadjuvant TherapyMastectomy, SegmentalPostoperative ComplicationsHumansFemaleRetrospective StudiesMiddle AgedAnesthesia, GeneralLength of StayAgedPerioperative CareOnco-anesthesiaAdult

Stichwörter der Autor:innen

Breast cancerGeneral anesthesiaImmunotherapyNeoadjuvant therapyPerioperative care

Autor:innen und Institutionen

  • Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Department of Anesthesiology, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Department of Nursing, Memorial Sloan Kettering Cancer Center, New York, NY; Hunter-Bellevue School of Nursing, City University of New York, New York, NY. Electronic address: Jennifer.majumdar@hunter.cuny.edu.

Förderung

  • NCI NIH HHS
  • Memorial Sloan-Kettering Cancer Center

Zitieren

APA

Sampathkumar, Y., Yu, R., Sepahpour, T. Y., Tokita, H. K., Rosa, W. E., Afonso, A., Vickers, A., Assel, M., Mamtani, A., & Majumdar, J. R. (2026). Intraoperative and Perioperative Outcomes of Breast-Conserving Surgery After Neoadjuvant Systemic Therapy: A Retrospective Cohort Study. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2026.08.005

Vancouver

Sampathkumar Y, Yu R, Sepahpour TY, Tokita HK, Rosa WE, Afonso A, et al. Intraoperative and Perioperative Outcomes of Breast-Conserving Surgery After Neoadjuvant Systemic Therapy: A Retrospective Cohort Study. Clinical Breast Cancer. 2026. doi:10.1016/j.clbc.2026.08.005

BibTeX
@article{Sampathkumar2026,
  author = {Sampathkumar, Yashasvini and Yu, Rebecca and Sepahpour, Tiana Y and Tokita, Hanae K and Rosa, William E and Afonso, Anoushka and Vickers, Andrew and Assel, Melissa and Mamtani, Anita and Majumdar, Jennifer R},
  title = {Intraoperative and Perioperative Outcomes of Breast-Conserving Surgery After Neoadjuvant Systemic Therapy: A Retrospective Cohort Study},
  journal = {Clinical Breast Cancer},
  year = {2026},
  doi = {10.1016/j.clbc.2026.08.005}
}
Kostenlos starten →